NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis $10.97 +0.01 (+0.10%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About 89bio Stock (NASDAQ:ETNB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 89bio alerts:Sign Up Key Stats Today's Range$10.94▼$11.2350-Day Range$6.09▼$11.6652-Week Range$5.99▼$16.63Volume211,394 shsAverage Volume2.72 million shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$31.43Consensus RatingModerate Buy Company Overview89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More… 89bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreETNB MarketRank™: 89bio scored higher than 63% of companies evaluated by MarketBeat, and ranked 390th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst Coverage89bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 89bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 89bio are expected to grow in the coming year, from ($3.19) to ($2.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 89bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.86% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in 89bio has recently decreased by 0.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.86% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in 89bio has recently decreased by 0.12%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.66 News Sentiment89bio has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 89bio this week, compared to 4 articles on an average week.Search Interest14 people have searched for ETNB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought 70,505.33% more of their company's stock than they have sold. Specifically, they have bought $50,235,694.00 in company stock and sold $71,150.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of 89bio is held by insiders.Read more about 89bio's insider trading history. Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ETNB Stock News Headlines89bio, Inc. (NASDAQ:ETNB) Director Acquires $49,999,993.75 in StockFebruary 4, 2025 | insidertrades.com89bio's (ETNB) Sell (D-) Rating Reaffirmed at Weiss RatingsFebruary 20 at 3:11 AM | americanbankingnews.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…February 21, 2025 | Investors Alley (Ad)Insider Buying Surges in February, Especially in These 6 StocksFebruary 9, 2025 | 247wallst.comInstitutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownershipFebruary 6, 2025 | uk.finance.yahoo.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2025 | globenewswire.comWolfe Research Initiates Coverage of 89bio (ETNB) with Outperform RecommendationFebruary 5, 2025 | msn.com89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesFebruary 3, 2025 | markets.businessinsider.comSee More Headlines ETNB Stock Analysis - Frequently Asked Questions How have ETNB shares performed this year? 89bio's stock was trading at $7.82 at the beginning of 2025. Since then, ETNB stock has increased by 41.3% and is now trading at $11.0460. View the best growth stocks for 2025 here. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings data on Monday, August, 5th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.08. When did 89bio IPO? 89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's top institutional shareholders include Janus Henderson Group PLC (15.56%), Suvretta Capital Management LLC (9.61%), RTW Investments LP (7.05%) and Deep Track Capital LP (6.10%). Insiders that own company stock include Ra Capital Management, LP, Rohan Palekar, Quoc Le-Nguyen, Ryan Martins and Kathleen Laporte. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 89bio investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT). Company Calendar Last Earnings8/05/2024Today2/21/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$31.43 High Stock Price Target$49.00 Low Stock Price Target$12.00 Potential Upside/Downside+184.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.58% Return on Assets-52.21% Debt Debt-to-Equity Ratio0.09 Current Ratio11.66 Quick Ratio11.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.92Miscellaneous Outstanding Shares106,126,000Free Float103,154,000Market Cap$1.17 billion OptionableOptionable Beta1.17 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ETNB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 89bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.